25 XP   0   0   10

Omeros Corporation
Buy, Hold or Sell?

Let's analyse Omeros together

PenkeI guess you are interested in Omeros Corporation. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Omeros Corporation. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Omeros Corporation

I send you an email if I find something interesting about Omeros Corporation.

Quick analysis of Omeros (30 sec.)










What can you expect buying and holding a share of Omeros? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$-0.40
Expected worth in 1 year
$-2.09
How sure are you?
20.5%

+ What do you gain per year?

Total Gains per Share
$-1.70
Return On Investment
-53.8%

For what price can you sell your share?

Current Price per Share
$3.15
Expected price per share
$1.13 - $4.85
How sure are you?
50%

1. Valuation of Omeros (5 min.)




Live pricePrice per Share (EOD)

$3.15

Intrinsic Value Per Share

$-16.19 - $-13.42

Total Value Per Share

$-16.58 - $-13.82

2. Growth of Omeros (5 min.)




Is Omeros growing?

Current yearPrevious yearGrowGrow %
How rich?-$24.9m$15.4m-$21.5m-350.8%

How much money is Omeros making?

Current yearPrevious yearGrowGrow %
Making money-$28m$33.7m-$61.7m-220.3%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

3. Financial Health of Omeros (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#969 / 1010

Most Revenue
#725 / 1010

Most Profit
#771 / 1010

Most Efficient
#161 / 1010

What can you expect buying and holding a share of Omeros? (5 min.)

Welcome investor! Omeros's management wants to use your money to grow the business. In return you get a share of Omeros.

What can you expect buying and holding a share of Omeros?

First you should know what it really means to hold a share of Omeros. And how you can make/lose money.

Speculation

The Price per Share of Omeros is $3.15. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Omeros.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Omeros, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $-0.40. Based on the TTM, the Book Value Change Per Share is $-0.42 per quarter. Based on the YOY, the Book Value Change Per Share is $0.24 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Omeros.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.14-4.6%-0.45-14.2%0.195.9%-0.06-2.0%-0.19-6.2%
Usd Book Value Change Per Share-0.18-5.6%-0.42-13.5%0.247.6%0.082.6%-0.01-0.4%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.18-5.6%-0.42-13.5%0.247.6%0.082.6%-0.01-0.4%
Usd Price Per Share3.45-3.94-3.20-9.58-13.05-
Price to Earnings Ratio-5.98--3.16--1.53--5.70--10.24-
Price-to-Total Gains Ratio-19.66--11.64--7.30--23.63--37.37-
Price to Book Ratio-8.68--1.72--0.65--6.81--17.56-
Price-to-Total Gains Ratio-19.66--11.64--7.30--23.63--37.37-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share3.15
Number of shares317
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.420.08
Usd Total Gains Per Share-0.420.08
Gains per Quarter (317 shares)-134.3325.49
Gains per Year (317 shares)-537.32101.95
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-537-547010292
20-1075-10840204194
30-1612-16210306296
40-2149-21580408398
50-2687-26950510500
60-3224-32320612602
70-3761-37690714704
80-4299-43060816806
90-4836-48430918908
100-5373-5380010201010

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.03.00.00.0%2.09.00.018.2%2.017.00.010.5%2.037.00.05.1%2.060.01.03.2%
Book Value Change Per Share0.03.00.00.0%2.09.00.018.2%4.015.00.021.1%8.031.00.020.5%15.046.02.023.8%
Dividend per Share0.00.03.00.0%0.00.011.00.0%0.00.019.00.0%0.00.039.00.0%0.00.063.00.0%
Total Gains per Share0.03.00.00.0%2.09.00.018.2%4.015.00.021.1%8.031.00.020.5%15.046.02.023.8%

Fundamentals of Omeros

About Omeros Corporation

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that is in phase Ib clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders; and OMS405 that is in phase II clinical trials for opioid and nicotine addiction. In addition, the company develops MASP-2-small-molecule inhibitors for the treatment of aHUS, HSCT-TMA, and age-related macular degeneration; GPR174 inhibitors and chimeric antigen receptor T-Cell and adoptive T-Cell therapies for various cancers; and G protein-coupled receptors for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.

Fundamental data was last updated by Penke on 2024-04-11 16:52:06.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is just not able to pay all its debts by selling its assets.
The company is unable to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Omeros Corporation.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Omeros earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Omeros to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Omeros Corporation:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-92.5%+92.5%
5Y-92.5%10Y-1,899.9%+1,807.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--207.2%+207.2%
TTM--216.8%+216.8%
YOY--282.3%+282.3%
5Y-92.5%-436.8%+344.3%
10Y-1,899.9%-597.3%-1,302.6%
1.1.2. Return on Assets

Shows how efficient Omeros is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Omeros to the Biotechnology industry mean.
  • -2.4% Return on Assets means that Omeros generated $-0.02 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Omeros Corporation:

  • The MRQ is -2.4%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -5.7%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-2.4%TTM-5.7%+3.3%
TTM-5.7%YOY6.2%-11.9%
TTM-5.7%5Y-8.4%+2.7%
5Y-8.4%10Y-25.0%+16.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.4%-13.3%+10.9%
TTM-5.7%-12.8%+7.1%
YOY6.2%-11.6%+17.8%
5Y-8.4%-13.8%+5.4%
10Y-25.0%-15.6%-9.4%
1.1.3. Return on Equity

Shows how efficient Omeros is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Omeros to the Biotechnology industry mean.
  • 0.0% Return on Equity means Omeros generated $0.00 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Omeros Corporation:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-60.6%+60.6%
TTM-60.6%YOY22.2%-82.8%
TTM-60.6%5Y57.2%-117.8%
5Y57.2%10Y23.5%+33.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--16.9%+16.9%
TTM-60.6%-16.1%-44.5%
YOY22.2%-14.9%+37.1%
5Y57.2%-19.3%+76.5%
10Y23.5%-20.1%+43.6%

1.2. Operating Efficiency of Omeros Corporation.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Omeros is operating .

  • Measures how much profit Omeros makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Omeros to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Omeros Corporation:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-57.5%+57.5%
5Y-57.5%10Y-1,780.9%+1,723.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--298.0%+298.0%
TTM--238.5%+238.5%
YOY--288.4%+288.4%
5Y-57.5%-486.2%+428.7%
10Y-1,780.9%-628.4%-1,152.5%
1.2.2. Operating Ratio

Measures how efficient Omeros is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Omeros Corporation:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y1.053-1.053
5Y1.05310Y33.372-32.319
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.235-3.235
TTM-3.310-3.310
YOY-3.838-3.838
5Y1.0535.679-4.626
10Y33.3727.823+25.549

1.3. Liquidity of Omeros Corporation.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Omeros is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 4.09 means the company has $4.09 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Omeros Corporation:

  • The MRQ is 4.087. The company is very able to pay all its short-term debts. +2
  • The TTM is 3.060. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ4.087TTM3.060+1.027
TTM3.060YOY4.637-1.576
TTM3.0605Y3.244-0.183
5Y3.24410Y2.988+0.256
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.0873.863+0.224
TTM3.0604.169-1.109
YOY4.6375.337-0.700
5Y3.2446.122-2.878
10Y2.9886.434-3.446
1.3.2. Quick Ratio

Measures if Omeros is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Omeros to the Biotechnology industry mean.
  • A Quick Ratio of 7.02 means the company can pay off $7.02 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Omeros Corporation:

  • The MRQ is 7.016. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 5.420. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ7.016TTM5.420+1.596
TTM5.420YOY6.676-1.256
TTM5.4205Y4.925+0.495
5Y4.92510Y4.764+0.162
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ7.0163.504+3.512
TTM5.4203.991+1.429
YOY6.6765.371+1.305
5Y4.9256.088-1.163
10Y4.7646.395-1.631

1.4. Solvency of Omeros Corporation.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Omeros assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Omeros to Biotechnology industry mean.
  • A Debt to Asset Ratio of 1.07 means that Omeros assets are financed with 106.6% credit (debt) and the remaining percentage (100% - 106.6%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Omeros Corporation:

  • The MRQ is 1.066. The company is just not able to pay all its debts by selling its assets. -1
  • The TTM is 1.018. The company is just not able to pay all its debts by selling its assets. -1
Trends
Current periodCompared to+/- 
MRQ1.066TTM1.018+0.048
TTM1.018YOY0.988+0.030
TTM1.0185Y1.705-0.686
5Y1.70510Y1.662+0.043
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.0660.339+0.727
TTM1.0180.337+0.681
YOY0.9880.271+0.717
5Y1.7050.368+1.337
10Y1.6620.388+1.274
1.4.2. Debt to Equity Ratio

Measures if Omeros is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Omeros to the Biotechnology industry mean.
  • A Debt to Equity ratio of 0.0% means that company has $0.00 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Omeros Corporation:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM8.238-8.238
TTM8.238YOY3.773+4.465
TTM8.2385Y2.971+5.268
5Y2.97110Y1.833+1.137
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.392-0.392
TTM8.2380.403+7.835
YOY3.7730.335+3.438
5Y2.9710.427+2.544
10Y1.8330.461+1.372

2. Market Valuation of Omeros Corporation

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Omeros generates.

  • Above 15 is considered overpriced but always compare Omeros to the Biotechnology industry mean.
  • A PE ratio of -5.98 means the investor is paying $-5.98 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Omeros Corporation:

  • The EOD is -5.459. Based on the earnings, the company is expensive. -2
  • The MRQ is -5.979. Based on the earnings, the company is expensive. -2
  • The TTM is -3.163. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-5.459MRQ-5.979+0.520
MRQ-5.979TTM-3.163-2.817
TTM-3.163YOY-1.532-1.630
TTM-3.1635Y-5.703+2.541
5Y-5.70310Y-10.239+4.536
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-5.459-2.300-3.159
MRQ-5.979-2.656-3.323
TTM-3.163-2.718-0.445
YOY-1.532-4.145+2.613
5Y-5.703-6.258+0.555
10Y-10.239-6.315-3.924
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Omeros Corporation:

  • The EOD is -1.417. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -1.552. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -1.859. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.417MRQ-1.552+0.135
MRQ-1.552TTM-1.859+0.307
TTM-1.859YOY-1.263-0.596
TTM-1.8595Y-7.942+6.082
5Y-7.94210Y-14.071+6.130
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.417-2.974+1.557
MRQ-1.552-3.306+1.754
TTM-1.859-3.508+1.649
YOY-1.263-5.613+4.350
5Y-7.942-8.378+0.436
10Y-14.071-8.873-5.198
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Omeros is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of -8.68 means the investor is paying $-8.68 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Omeros Corporation:

  • The EOD is -7.926. Based on the equity, the company is expensive. -2
  • The MRQ is -8.681. Based on the equity, the company is expensive. -2
  • The TTM is -1.721. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-7.926MRQ-8.681+0.755
MRQ-8.681TTM-1.721-6.960
TTM-1.721YOY-0.646-1.076
TTM-1.7215Y-6.813+5.092
5Y-6.81310Y-17.555+10.742
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-7.9261.914-9.840
MRQ-8.6812.116-10.797
TTM-1.7212.097-3.818
YOY-0.6462.881-3.527
5Y-6.8133.550-10.363
10Y-17.5553.936-21.491
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Omeros Corporation.

3.1. Institutions holding Omeros Corporation

Institutions are holding 39.858% of the shares of Omeros Corporation.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Ingalls & Snyder LLC7.23250.67224546762-96824-2.0851
2023-12-31BlackRock Inc6.80790.000442798362544846.322
2023-12-31Vanguard Group Inc5.04080.00023168936260850.83
2023-12-31Stifel Financial Corp3.00750.00781890674-137243-6.7677
2023-09-30D. E. Shaw & Co LP2.16560.00421361436-277766-16.9452
2023-12-31Geode Capital Management, LLC2.12950.00051338713559674.3631
2023-12-31State Street Corporation1.91030.00021200928385413.3157
2023-12-31CI Private Wealth LLC1.05570.004663663-23246-3.3841
2023-12-31Bank of Montreal0.89570.0006563096-201-0.0357
2023-12-31BMO Capital Markets Corp.0.89570.0006563096-201-0.0357
2023-12-31Northern Trust Corp0.88930.0003559052130092.3824
2023-12-31Royal Bank of Canada0.80960.0004508940-1546959-75.2449
2023-12-31UBS Group AG0.78670.0005494546-96096-16.2698
2023-12-31Charles Schwab Investment Management Inc0.74630.0004469174-21794-4.439
2023-12-31Nomura Holdings Inc0.60950.0034383144-62338-13.9934
2023-12-31Morgan Stanley - Brokerage Accounts0.44920.00012824054442718.6685
2023-12-31Group One Trading, LP0.36720.00223085391544.129
2023-12-31Bank of New York Mellon Corp0.32180.0001202314-408-0.2013
2023-12-31Bridgeway Capital Management, LLC0.29630.01311863007710070.6044
2023-12-31First Trust Advisors L.P.0.27480.000617275541302.4492
Total 36.69190.711623066623-1740179-7.5%

3.2. Funds holding Omeros Corporation

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29Vanguard Total Stock Mkt Idx Inv2.98530.0005187674400
2024-02-29iShares Russell 2000 ETF2.2770.01031431432-234-0.0163
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr1.48890.004193599800
2023-12-31Fidelity Small Cap Index0.96230.007860496873061.2224
2024-02-29State St Russell Sm/Mid Cp® Indx NL Cl C0.58950.00437060039001.0635
2024-02-01iShares Russell 2000 Value ETF0.5730.01043602474560.1267
2024-01-31Fidelity Extended Market Index0.55240.003134729500
2024-02-29Schwab US Small-Cap ETF™0.47680.008329975900
2024-02-29State St Russell Sm Cap® Indx SL Cl I0.3570.010722440000
2024-02-29Vanguard Russell 2000 ETF0.34820.0103218912174448.6584
2024-02-29iShares Russell 2000 Growth ETF0.33790.0084212430-247-0.1161
2023-12-31NT R2000 Index Fund - NL0.28460.008117892487625.1492
2024-02-29First Trust Dow Jones Sel MicroCap ETF0.28380.463217840600
2023-12-31Bridgeway Ultra-Small Company Market0.28090.31081766006740061.7216
2023-09-30BlackRock Extended Mkt Composite0.2430.003215276410650.702
2023-12-31NT R2000 Index Fund - DC - NL - 20.22410.008114090563834.7449
2024-02-29Schwab Small Cap Index0.22140.010613917100
2024-02-29iShares Micro-Cap ETF0.21640.067213604500
2023-12-31BlackRock Extended Equity Market K0.20950.0031131705-265-0.2008
2023-12-31Russell 2000 Index Non-Lendable Fund E0.18110.0082113839-134-0.1176
Total 13.09310.96048231144+111836+1.4%

3.3. Insider Transactions

Insiders are holding 4.036% of the shares of Omeros Corporation.

DateOwnerTypeAmountPricePost Transaction AmountLink
2023-11-17Gregory A Md DemopulosBUY150001.68
2023-11-15Peter A Md DemopulosBUY100001.53
2023-05-22Arnold C. HanishSELL50006.46

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Omeros Corporation compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.175-0.424+141%0.238-174%0.080-318%-0.012-93%
Book Value Per Share---0.397-0.098-75%0.245-262%-1.297+226%-0.847+113%
Current Ratio--4.0873.060+34%4.637-12%3.244+26%2.988+37%
Debt To Asset Ratio--1.0661.018+5%0.988+8%1.705-37%1.662-36%
Debt To Equity Ratio---8.238-100%3.773-100%2.971-100%1.833-100%
Dividend Per Share----0%-0%-0%-0%
Eps---0.144-0.446+209%0.186-178%-0.062-57%-0.195+35%
Free Cash Flow Per Share---0.556-0.531-4%0.410-236%-0.226-59%-0.240-57%
Free Cash Flow To Equity Per Share---2.225-1.092-51%0.902-347%-0.009-100%-0.006-100%
Gross Profit Margin--1.0001.0000%1.0000%0.997+0%0.998+0%
Intrinsic Value_10Y_max---13.419--------
Intrinsic Value_10Y_min---16.185--------
Intrinsic Value_1Y_max---0.602--------
Intrinsic Value_1Y_min---1.079--------
Intrinsic Value_3Y_max---2.374--------
Intrinsic Value_3Y_min---3.731--------
Intrinsic Value_5Y_max---4.829--------
Intrinsic Value_5Y_min---6.899--------
Market Cap198026325.000-10%216885975.000247480518.333-12%201326763.750+8%602450012.632-64%820370595.962-74%
Net Profit Margin----0%-0%-0.9250%-18.9990%
Operating Margin----0%-0%-0.5750%-17.8090%
Operating Ratio----0%-0%1.053-100%33.372-100%
Pb Ratio-7.926+9%-8.681-1.721-80%-0.646-93%-6.813-22%-17.555+102%
Pe Ratio-5.459+9%-5.979-3.163-47%-1.532-74%-5.703-5%-10.239+71%
Price Per Share3.150-10%3.4503.937-12%3.203+8%9.583-64%13.050-74%
Price To Free Cash Flow Ratio-1.417+9%-1.552-1.859+20%-1.263-19%-7.942+412%-14.071+807%
Price To Total Gains Ratio-17.952+9%-19.661-11.641-41%-7.301-63%-23.634+20%-37.372+90%
Quick Ratio--7.0165.420+29%6.676+5%4.925+42%4.764+47%
Return On Assets---0.024-0.057+138%0.062-138%-0.084+251%-0.250+942%
Return On Equity----0.6060%0.222-100%0.572-100%0.235-100%
Total Gains Per Share---0.175-0.424+141%0.238-174%0.080-318%-0.012-93%
Usd Book Value---24983000.000-6141666.667-75%15401000.000-262%-81544000.000+226%-53244717.949+113%
Usd Book Value Change Per Share---0.175-0.424+141%0.238-174%0.080-318%-0.012-93%
Usd Book Value Per Share---0.397-0.098-75%0.245-262%-1.297+226%-0.847+113%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.144-0.446+209%0.186-178%-0.062-57%-0.195+35%
Usd Free Cash Flow---34943000.000-33413000.000-4%25758250.000-236%-14212842.105-59%-15077615.385-57%
Usd Free Cash Flow Per Share---0.556-0.531-4%0.410-236%-0.226-59%-0.240-57%
Usd Free Cash Flow To Equity Per Share---2.225-1.092-51%0.902-347%-0.009-100%-0.006-100%
Usd Market Cap198026325.000-10%216885975.000247480518.333-12%201326763.750+8%602450012.632-64%820370595.962-74%
Usd Price Per Share3.150-10%3.4503.937-12%3.203+8%9.583-64%13.050-74%
Usd Profit---9068000.000-28037333.333+209%33732750.000-127%494315.789-1934%-10104153.846+11%
Usd Revenue----0%-0%8623052.632-100%8612205.128-100%
Usd Total Gains Per Share---0.175-0.424+141%0.238-174%0.080-318%-0.012-93%
 EOD+2 -6MRQTTM+14 -14YOY+8 -215Y+14 -1810Y+15 -17

4.2. Fundamental Score

Let's check the fundamental score of Omeros Corporation based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-5.459
Price to Book Ratio (EOD)Between0-1-7.926
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than17.016
Current Ratio (MRQ)Greater than14.087
Debt to Asset Ratio (MRQ)Less than11.066
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.05-0.024
Total3/10 (30.0%)

4.3. Technical Score

Let's check the technical score of Omeros Corporation based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5042.275
Ma 20Greater thanMa 503.298
Ma 50Greater thanMa 1003.781
Ma 100Greater thanMa 2003.540
OpenGreater thanClose3.070
Total2/5 (40.0%)



Latest Balance Sheet

Balance Sheet of 2024-03-31. All numbers in thousands.

Summary
Total Assets378,269
Total Liabilities403,252
Total Stockholder Equity-24,983
 As reported
Total Liabilities 403,252
Total Stockholder Equity+ -24,983
Total Assets = 378,269

Assets

Total Assets378,269
Total Current Assets217,898
Long-term Assets160,371
Total Current Assets
Cash And Cash Equivalents 7,105
Short-term Investments 164,743
Net Receivables 37,469
Other Current Assets 8,581
Total Current Assets  (as reported)217,898
Total Current Assets  (calculated)217,898
+/-0
Long-term Assets
Property Plant Equipment 20,581
Long-term Assets  (as reported)160,371
Long-term Assets  (calculated)20,581
+/- 139,790

Liabilities & Shareholders' Equity

Total Current Liabilities53,316
Long-term Liabilities349,936
Total Stockholder Equity-24,983
Total Current Liabilities
Short-term Debt 13,736
Accounts payable 7,712
Other Current Liabilities 31,868
Total Current Liabilities  (as reported)53,316
Total Current Liabilities  (calculated)53,316
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)349,936
Long-term Liabilities  (calculated)0
+/- 349,936
Total Stockholder Equity
Common Stock611
Retained Earnings -753,530
Other Stockholders Equity 727,936
Total Stockholder Equity (as reported)-24,983
Total Stockholder Equity (calculated)-24,983
+/-0
Other
Cash and Short Term Investments 171,848
Common Stock Shares Outstanding 62,441
Liabilities and Stockholders Equity 378,269
Net Debt 354,479
Net Working Capital 164,582
Short Long Term Debt Total 361,584



Balance Sheet

All numbers in thousands.

 Trend2024-03-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302007-12-31
> Total Assets 
27,162
0
21,681
0
12,682
6,910
62,062
53,486
44,786
37,106
45,704
47,753
40,948
34,984
26,982
21,089
10,066
32,761
26,575
17,693
23,058
12,014
16,535
56,067
40,993
25,294
11,090
74,911
58,637
41,417
48,995
35,972
46,108
72,763
67,278
58,404
60,354
125,517
116,328
89,035
106,349
75,610
95,936
101,246
89,760
91,263
136,969
118,214
70,689
227,075
181,042
161,444
145,391
123,430
419,268
369,263
345,638
457,551
590,969
560,132
527,421
493,071
378,269
378,269493,071527,421560,132590,969457,551345,638369,263419,268123,430145,391161,444181,042227,07570,689118,214136,96991,26389,760101,24695,93675,610106,34989,035116,328125,51760,35458,40467,27872,76346,10835,97248,99541,41758,63774,91111,09025,29440,99356,06716,53512,01423,05817,69326,57532,76110,06621,08926,98234,98440,94847,75345,70437,10644,78653,48662,0626,91012,682021,681027,162
   > Total Current Assets 
0
0
20,478
0
11,116
4,940
60,664
51,777
43,032
35,185
43,754
45,277
39,667
33,839
25,948
19,698
8,520
31,437
24,700
15,813
21,271
10,270
14,817
54,132
38,968
23,361
9,157
73,066
56,681
39,463
37,146
24,322
34,105
60,649
60,262
51,354
53,093
117,897
108,372
78,684
96,504
66,001
89,867
76,871
65,944
63,799
103,745
85,611
38,927
195,985
151,285
132,482
112,401
91,349
247,889
210,222
192,722
288,545
443,236
417,037
388,558
351,338
217,898
217,898351,338388,558417,037443,236288,545192,722210,222247,88991,349112,401132,482151,285195,98538,92785,611103,74563,79965,94476,87189,86766,00196,50478,684108,372117,89753,09351,35460,26260,64934,10524,32237,14639,46356,68173,0669,15723,36138,96854,13214,81710,27021,27115,81324,70031,4378,52019,69825,94833,83939,66745,27743,75435,18543,03251,77760,6644,94011,116020,47800
       Cash And Cash Equivalents 
5,925
0
12,726
0
1,283
1,367
820
814
2,873
2,796
3,278
3,921
4,159
4,888
4,005
16,802
7,268
1,060
1,520
1,281
1,716
1,150
1,384
567
1,533
750
354
1,441
2,561
601
1,365
978
4,589
10,297
2,224
1,282
3,386
1,026
3,394
1,189
2,883
2,787
5,861
4,054
3,986
8,861
3,084
7,118
1,964
21,075
10,501
9,028
12,702
7,415
100,808
8,963
14,136
145,533
11,009
3,829
6,603
30,640
7,105
7,10530,6406,6033,82911,009145,53314,1368,963100,8087,41512,7029,02810,50121,0751,9647,1183,0848,8613,9864,0545,8612,7872,8831,1893,3941,0263,3861,2822,22410,2974,5899781,3656012,5611,4413547501,5335671,3841,1501,7161,2811,5201,0607,26816,8024,0054,8884,1593,9213,2782,7962,8738148201,3671,283012,72605,925
       Short-term Investments 
18,157
0
7,256
0
9,080
3,125
59,485
50,259
39,010
31,715
38,715
39,715
32,715
27,965
20,565
815
0
29,569
20,830
12,035
18,346
7,848
12,717
51,622
35,927
21,030
6,532
68,621
48,885
34,398
26,898
12,266
16,648
37,144
43,107
32,371
26,281
85,787
80,355
71,625
85,521
52,369
54,637
43,168
27,859
18,481
57,704
46,862
14,124
132,448
124,452
91,455
60,956
42,957
56,458
133,271
108,427
75,431
183,909
367,527
334,680
279,670
164,743
164,743279,670334,680367,527183,90975,431108,427133,27156,45842,95760,95691,455124,452132,44814,12446,86257,70418,48127,85943,16854,63752,36985,52171,62580,35585,78726,28132,37143,10737,14416,64812,26626,89834,39848,88568,6216,53221,03035,92751,62212,7177,84818,34612,03520,83029,569081520,56527,96532,71539,71538,71531,71539,01050,25959,4853,1259,08007,256018,157
       Net Receivables 
0
0
207
0
570
320
248
555
935
500
1,479
1,295
2,460
776
876
1,643
767
467
1,934
2,003
715
881
379
488
252
381
392
538
3,071
2,510
6,517
6,646
8,806
10,457
12,037
13,481
19,075
24,571
17,144
182
1,529
2,297
22,818
24,718
28,515
29,931
35,185
24,117
15,780
37,379
3,841
24,826
31,838
33,898
82,474
60,365
58,273
61,598
242,018
38,973
40,274
36,106
37,469
37,46936,10640,27438,973242,01861,59858,27360,36582,47433,89831,83824,8263,84137,37915,78024,11735,18529,93128,51524,71822,8182,2971,52918217,14424,57119,07513,48112,03710,4578,8066,6466,5172,5103,0715383923812524883798817152,0031,9344677671,6438767762,4601,2951,479500935555248320570020700
       Inventory 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,312
1,110
1,052
568
566
633
445
472
1,972
1,780
1,396
1,128
960
905
822
443
247
235
214
52,511
736
1,187
1,173
48,286
1,211
1,892
1,542
114,549
1,191
978
712
0
0
-43,794
-47,744
0
0
0
0
0
00000-47,744-43,794007129781,191114,5491,5421,8921,21148,2861,1731,18773652,5112142352474438229059601,1281,3961,7801,9724724456335665681,0521,1101,31200000000000000000000000
   > Long-term Assets 
0
0
1,203
0
1,566
1,970
1,398
1,709
1,754
1,921
1,950
2,476
1,281
1,145
1,034
1,391
1,546
1,324
1,875
1,880
1,787
1,744
1,718
1,935
2,025
1,933
1,933
1,845
1,956
1,954
11,849
11,650
12,003
12,114
7,016
7,050
7,261
7,620
7,956
10,351
9,845
9,609
6,069
24,375
23,816
27,464
33,224
32,603
31,762
31,090
29,757
28,962
32,990
32,081
171,379
159,041
152,916
169,006
147,733
143,095
138,863
141,733
160,371
160,371141,733138,863143,095147,733169,006152,916159,041171,37932,08132,99028,96229,75731,09031,76232,60333,22427,46423,81624,3756,0699,6099,84510,3517,9567,6207,2617,0507,01612,11412,00311,65011,8491,9541,9561,8451,9331,9332,0251,9351,7181,7441,7871,8801,8751,3241,5461,3911,0341,1451,2812,4761,9501,9211,7541,7091,3981,9701,56601,20300
       Property Plant Equipment 
839
0
918
0
775
681
1,086
1,426
1,498
1,642
1,622
2,127
952
833
739
726
660
685
1,037
1,058
981
952
939
989
907
846
782
727
789
808
951
898
1,251
1,206
1,181
1,215
1,426
1,785
2,121
2,081
2,436
2,520
3,845
21,993
21,501
25,089
30,911
30,436
29,712
29,066
28,077
27,167
31,731
30,870
30,007
24,362
25,050
24,311
23,254
22,360
22,007
21,177
20,581
20,58121,17722,00722,36023,25424,31125,05024,36230,00730,87031,73127,16728,07729,06629,71230,43630,91125,08921,50121,9933,8452,5202,4362,0812,1211,7851,4261,2151,1811,2061,2518989518087897277828469079899399529811,0581,0376856607267398339522,1271,6221,6421,4981,4261,08668177509180839
       Intangible Assets 
164
0
60
0
9
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000000000000000000000000000000000000090600164
       Long-term Assets Other 
0
0
225
0
782
1,289
312
283
256
279
328
349
329
312
295
665
886
639
838
822
806
792
779
946
1,118
1,087
1,151
1,118
1,167
1,146
10,898
10,752
10,752
10,908
5,835
5,835
5,835
5,835
5,835
8,270
7,409
7,089
1,070
2,382
2,315
2,375
2,313
2,167
2,050
2,024
1,680
1,795
1,259
1,211
141,372
134,679
127,866
144,695
124,479
120,735
116,856
120,556
0
0120,556116,856120,735124,479144,695127,866134,679141,3721,2111,2591,7951,6802,0242,0502,1672,3132,3752,3152,3821,0707,0897,4098,2705,8355,8355,8355,8355,83510,90810,75210,75210,8981,1461,1671,1181,1511,0871,1189467797928068228386398866652953123293493282792562833121,289782022500
> Total Liabilities 
7,935
0
112,847
0
114,330
112,203
18,917
16,498
14,988
14,194
25,234
33,081
30,933
30,907
32,536
33,772
30,603
33,581
241,152
33,557
35,314
35,907
34,919
50,855
51,604
51,883
53,744
53,065
50,705
50,421
75,229
76,714
95,103
95,535
104,725
106,517
115,204
116,306
119,142
118,250
162,646
164,607
-4,220
222,265
220,034
231,178
245,990
250,078
231,959
314,401
301,794
383,399
391,687
386,127
395,488
374,188
378,340
503,865
505,285
505,196
506,911
507,023
403,252
403,252507,023506,911505,196505,285503,865378,340374,188395,488386,127391,687383,399301,794314,401231,959250,078245,990231,178220,034222,265-4,220164,607162,646118,250119,142116,306115,204106,517104,72595,53595,10376,71475,22950,42150,70553,06553,74451,88351,60450,85534,91935,90735,31433,557241,15233,58130,60333,77232,53630,90730,93333,08125,23414,19414,98816,49818,917112,203114,3300112,84707,935
   > Total Current Liabilities 
7,935
0
23,561
0
23,217
11,940
11,090
10,122
10,114
5,321
15,874
15,023
14,339
15,815
18,985
18,742
17,249
21,811
9,318
10,585
10,900
11,900
11,873
10,232
12,170
14,397
18,431
20,068
20,096
22,273
16,253
17,521
16,065
16,057
16,071
16,973
24,753
24,690
26,307
24,630
24,442
24,587
37,356
44,505
40,673
46,753
55,459
57,936
38,047
47,719
36,736
43,434
47,697
42,818
51,789
35,066
38,501
39,514
136,683
139,191
143,538
147,176
53,316
53,316147,176143,538139,191136,68339,51438,50135,06651,78942,81847,69743,43436,73647,71938,04757,93655,45946,75340,67344,50537,35624,58724,44224,63026,30724,69024,75316,97316,07116,05716,06517,52116,25322,27320,09620,06818,43114,39712,17010,23211,87311,90010,90010,5859,31821,81117,24918,74218,98515,81514,33915,02315,8745,32110,11410,12211,09011,94023,217023,56107,935
       Short-term Debt 
0
0
16,556
0
15,098
4,750
4,931
5,104
5,269
67
395
2,202
3,719
5,275
5,895
6,050
6,210
6,373
0
997
2,485
4,019
5,600
5,600
1,609
3,991
6,446
9,019
9,294
9,577
73
69
193
190
198
228
250
368
490
513
608
560
889
2,561
2,636
3,055
3,504
3,597
3,702
3,754
3,782
3,803
4,874
5,092
5,255
3,925
4,145
4,409
98,691
98,981
99,416
99,797
13,736
13,73699,79799,41698,98198,6914,4094,1453,9255,2555,0924,8743,8033,7823,7543,7023,5973,5043,0552,6362,56188956060851349036825022819819019369739,5779,2949,0196,4463,9911,6095,6005,6004,0192,48599706,3736,2106,0505,8955,2753,7192,202395675,2695,1044,9314,75015,098016,55600
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
6,330
0
0
0
49,842
0
193
190
79,710
228
81,761
83,146
84,607
85,550
130,358
0
0
1,415
0
0
0
0
0
0
0
0
0
0
0
0
0
0
94,381
94,554
94,730
94,909
0
094,90994,73094,55494,381000000000000001,41500130,35885,55084,60783,14681,76122879,710190193049,8420006,33000000000000000000000000000
       Accounts payable 
2,567
0
1,229
0
1,475
1,530
2,620
1,136
1,100
1,414
2,398
1,639
814
1,647
2,002
2,394
1,285
2,702
2,632
2,609
4,253
3,361
2,329
4,926
5,085
4,156
4,915
4,611
4,045
4,575
6,428
5,332
5,420
3,985
2,519
2,409
2,572
3,680
6,691
10,183
11,850
8,847
6,281
7,121
6,260
9,702
5,328
12,960
8,507
7,017
4,199
11,499
9,502
10,026
13,400
7,345
10,876
17,089
5,989
6,446
9,552
5,866
7,712
7,7125,8669,5526,4465,98917,08910,8767,34513,40010,0269,50211,4994,1997,0178,50712,9605,3289,7026,2607,1216,2818,84711,85010,1836,6913,6802,5722,4092,5193,9855,4205,3326,4284,5754,0454,6114,9154,1565,0854,9262,3293,3614,2532,6092,6322,7021,2852,3942,0021,6478141,6392,3981,4141,1001,1362,6201,5301,47501,22902,567
       Other Current Liabilities 
4,358
0
5,544
0
5,375
4,641
2,837
3,267
3,267
3,478
5,067
3,899
3,018
2,611
5,340
5,303
6,016
10,326
5,716
6,979
4,162
4,520
3,944
5,306
5,476
6,250
7,070
6,438
6,757
8,121
9,752
12,120
10,452
11,882
13,552
14,564
22,181
21,010
19,616
14,447
12,592
15,740
31,075
37,384
34,413
37,051
50,131
44,976
29,540
40,702
32,347
28,132
33,321
27,700
33,134
23,796
23,480
18,016
32,003
33,764
4,777
6,654
31,868
31,8686,6544,77733,76432,00318,01623,48023,79633,13427,70033,32128,13232,34740,70229,54044,97650,13137,05134,41337,38431,07515,74012,59214,44719,61621,01022,18114,56413,55211,88210,45212,1209,7528,1216,7576,4387,0706,2505,4765,3063,9444,5204,1626,9795,71610,3266,0165,3035,3402,6113,0183,8995,0673,4783,2673,2672,8374,6415,37505,54404,358
   > Long-term Liabilities 
0
0
89,286
0
91,113
100,263
7,827
6,376
4,874
8,873
9,360
18,058
16,594
15,092
13,551
15,030
13,354
11,770
231,834
22,972
24,414
24,007
23,046
40,623
39,434
37,486
35,313
32,997
30,609
28,148
58,976
59,193
79,038
79,478
88,654
89,544
90,451
91,616
92,835
93,620
138,204
140,020
-41,576
177,760
179,361
184,425
190,531
192,142
193,912
266,682
265,058
339,965
343,990
343,309
343,699
339,122
339,839
464,351
368,602
366,005
363,373
359,847
349,936
349,936359,847363,373366,005368,602464,351339,839339,122343,699343,309343,990339,965265,058266,682193,912192,142190,531184,425179,361177,760-41,576140,020138,20493,62092,83591,61690,45189,54488,65479,47879,03859,19358,97628,14830,60932,99735,31337,48639,43440,62323,04624,00724,41422,972231,83411,77013,35415,03013,55115,09216,59418,0589,3608,8734,8746,3767,827100,26391,113089,28600
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
16,594
15,092
13,551
11,969
10,345
8,679
20,103
19,200
17,809
16,376
14,898
32,212
30,761
28,551
26,263
23,906
21,477
18,974
49,769
49,973
69,833
70,289
79,512
80,503
81,511
82,778
84,117
85,037
129,750
131,695
150,559
151,182
153,416
155,771
158,213
160,746
163,372
232,808
236,288
312,159
312,585
313,018
313,458
313,904
314,358
314,819
220,906
221,209
221,516
0
0
00221,516221,209220,906314,819314,358313,904313,458313,018312,585312,159236,288232,808163,372160,746158,213155,771153,416151,182150,559131,695129,75085,03784,11782,77881,51180,50379,51270,28969,83349,97349,76918,97421,47723,90626,26328,55130,76132,21214,89816,37617,80919,20020,1038,67910,34511,96913,55115,09216,594000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,061
3,009
3,091
3,685
3,772
6,605
7,631
8,148
8,411
8,673
8,935
8,908
9,091
9,132
9,174
9,207
9,220
9,205
9,189
9,142
9,041
8,940
8,838
8,718
8,583
8,454
8,325
8,177
0
0
0
0
0
0
4,157
0
0
0
0
1,115
922
961
125,999
444
0
496
0
0
004960444125,9999619221,11500004,1570000008,1778,3258,4548,5838,7188,8388,9409,0419,1429,1899,2059,2209,2079,1749,1329,0918,9088,9358,6738,4118,1487,6316,6053,7723,6853,0913,0093,061000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,061
3,009
3,091
3,685
3,772
6,605
7,631
8,148
8,411
8,673
8,935
9,050
9,091
9,132
9,174
9,207
9,220
9,205
9,189
9,142
9,041
8,940
8,838
8,718
8,583
8,454
8,325
8,177
0
0
0
0
0
0
4,157
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000004,1570000008,1778,3258,4548,5838,7188,8388,9409,0419,1429,1899,2059,2209,2079,1749,1329,0919,0508,9358,6738,4118,1487,6316,6053,7723,6853,0913,0093,061000000000000000
> Total Stockholder Equity
19,227
0
-91,166
0
-101,648
-105,293
43,145
36,988
29,798
22,912
20,470
14,672
10,015
4,077
-5,554
-12,683
-20,537
-820
-214,577
-15,864
-12,256
-23,893
-18,384
5,212
-10,611
-26,589
-42,654
21,846
-363,395
-9,004
-26,234
-40,742
-48,995
-22,772
-37,447
-48,113
-54,850
9,211
-2,814
-29,215
-56,297
-88,997
650,125
-121,019
-130,274
-139,915
-109,021
-131,864
-161,270
-87,326
-872,672
-221,955
-246,296
-262,697
23,780
-4,925
-32,702
-46,314
85,684
54,936
20,510
-13,952
-24,983
-24,983-13,95220,51054,93685,684-46,314-32,702-4,92523,780-262,697-246,296-221,955-872,672-87,326-161,270-131,864-109,021-139,915-130,274-121,019650,125-88,997-56,297-29,215-2,8149,211-54,850-48,113-37,447-22,772-48,995-40,742-26,234-9,004-363,39521,846-42,654-26,589-10,6115,212-18,384-23,893-12,256-15,864-214,577-820-20,537-12,683-5,5544,07710,01514,67220,47022,91229,79836,98843,145-105,293-101,6480-91,166019,227
   Common Stock
29
0
57
0
30
30
213
213
214
215
219
221
222
223
224
225
225
259
259
259
298
298
304
339
340
340
342
378
379
380
380
391
393
429
438
439
444
480
482
483
485
490
490
490
492
495
542
545
545
616
616
622
624
625
626
627
627
627
721,401
628
628
628
611
611628628628721,4016276276276266256246226166165455455424954924904904904854834824804444394384293933913803803793783423403403393042982982592592592252252242232222212192152142132133030057029
   Retained Earnings Total Equity00-706,712-669,418-635,717-764,450-746,994-716,145-683,134-963,755-941,052-912,459-872,672-835,399-796,936-763,642-734,611-705,386-688,923-674,470-650,125-626,591-587,118-553,422-523,368-506,817-499,335-484,976-469,887-450,255-436,293-423,681-403,142-383,316-363,395-346,715-328,046-307,333-289,006-271,015-254,373-252,528-238,658-225,066-214,577-206,843-193,567-185,028-176,133-165,932-159,420000000000000
   Accumulated Other Comprehensive Income 
0
0
-99
0
56
23
41
42
0
0
-2,083
-2,083
0
0
-2,479
-2,479
0
0
-1,789
-1,789
0
0
-2,091
-2,091
0
0
-2,228
-2,228
0
0
-2,432
-2,432
0
0
-2,732
-2,732
0
0
-3,283
-3,283
0
0
-4,245
-4,622
-5,072
-5,507
-6,035
-6,437
-6,849
-7,253
0
-8,037
0
0
0
0
0
0
0
0
0
0
0
00000000000-8,0370-7,253-6,849-6,437-6,035-5,507-5,072-4,622-4,24500-3,283-3,28300-2,732-2,73200-2,432-2,43200-2,228-2,22800-2,091-2,09100-1,789-1,78900-2,479-2,47900-2,083-2,08300424123560-9900
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
169,213
169,786
170,355
172,120
172,805
205,764
207,787
208,943
226,104
228,337
235,685
275,888
278,055
280,404
285,050
368,183
370,948
373,932
376,528
382,548
386,905
427,054
432,002
436,424
444,041
515,548
520,072
523,724
530,336
537,104
549,479
552,961
558,157
564,976
625,048
631,233
635,121
747,457
751,304
689,882
694,132
700,433
706,288
710,593
713,665
717,509
720,773
723,726
726,594
0
0
00726,594723,726720,773717,509713,665710,593706,288700,433694,132689,882751,304747,457635,121631,233625,048564,976558,157552,961549,479537,104530,336523,724520,072515,548444,041436,424432,002427,054386,905382,548376,528373,932370,948368,183285,050280,404278,055275,888235,685228,337226,104208,943207,787205,764172,805172,120170,355169,786169,213000000000000
   Treasury Stock000000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
6,024
0
7,134
6,506
162,905
161,772
162,385
163,053
169,921
168,580
169,213
169,786
172,834
172,120
172,805
205,764
209,576
208,943
226,104
228,337
237,776
275,888
278,055
280,404
287,278
368,183
-379
373,932
378,960
382,548
386,905
427,054
434,734
436,424
444,041
515,548
523,355
523,724
530,336
537,104
553,724
557,583
563,229
570,483
631,083
637,670
641,970
754,710
-616
697,919
694,132
700,433
706,288
710,593
713,665
717,509
720,773
723,726
726,594
729,882
727,936
727,936729,882726,594723,726720,773717,509713,665710,593706,288700,433694,132697,919-616754,710641,970637,670631,083570,483563,229557,583553,724537,104530,336523,724523,355515,548444,041436,424434,734427,054386,905382,548378,960373,932-379368,183287,278280,404278,055275,888237,776228,337226,104208,943209,576205,764172,805172,120172,834169,786169,213168,580169,921163,053162,385161,772162,9056,5067,13406,02400



Balance Sheet

All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue-920
Gross Profit-920-920
 
Operating Income (+$)
Gross Profit-920
Operating Expense-163,610
Operating Income-164,530-164,530
 
Operating Expense (+$)
Research Development114,870
Selling General Administrative52,374
Selling And Marketing Expenses0
Operating Expense163,610167,244
 
Net Interest Income (+$)
Interest Income14,906
Interest Expense-30,844
Other Finance Cost-840
Net Interest Income-16,778
 
Pretax Income (+$)
Operating Income-164,530
Net Interest Income-16,778
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-174,920-154,140
EBIT - interestExpense = -195,374
-174,920
-86,969
Interest Expense30,844
Earnings Before Interest and Taxes (EBIT)-164,530-144,076
Earnings Before Interest and Taxes (EBITDA)-163,610
 
After tax Income (+$)
Income Before Tax-174,920
Tax Provision-0
Net Income From Continuing Ops-181,681-174,920
Net Income-117,813
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses164,530
Total Other Income/Expenses Net-10,39016,778
 

Technical Analysis of Omeros
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Omeros. The general trend of Omeros is BEARISH with 28.6% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Omeros's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-28.6%) Bearish trend (28.6%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Omeros Corporation.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 4.03 < 4.1 < 4.85.

The bearish price targets are: 2.76 > 2.612 > 1.13.

Tweet this
Omeros Corporation Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Omeros Corporation. The current mas is .

The long score for the Moving Averages is 5/14.
The longshort score for the Moving Averages is -4/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Omeros Corporation Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Omeros Corporation. The current macd is -0.15896693.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Omeros price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Omeros. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Omeros price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Omeros Corporation Daily Moving Average Convergence/Divergence (MACD) ChartOmeros Corporation Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Omeros Corporation. The current adx is 16.22.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -1/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Omeros shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Omeros Corporation Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Omeros Corporation. The current sar is 3.79161546.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Omeros Corporation Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Omeros Corporation. The current rsi is 42.28. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending up: The RSI is trending up. +1
Omeros Corporation Daily Relative Strength Index (RSI) ChartOmeros Corporation Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Omeros Corporation. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 0/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Omeros price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Omeros Corporation Daily Stochastic Oscillator ChartOmeros Corporation Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Omeros Corporation. The current cci is -55.46414397.

Omeros Corporation Daily Commodity Channel Index (CCI) ChartOmeros Corporation Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Omeros Corporation. The current cmo is -15.60466175.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Omeros Corporation Daily Chande Momentum Oscillator (CMO) ChartOmeros Corporation Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Omeros Corporation. The current willr is -83.70044053.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Omeros Corporation Daily Williams %R ChartOmeros Corporation Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Omeros Corporation.

Omeros Corporation Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Omeros Corporation. The current atr is 0.24300276.

Omeros Corporation Daily Average True Range (ATR) ChartOmeros Corporation Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Omeros Corporation. The current obv is 1,078,719.

Omeros Corporation Daily On-Balance Volume (OBV) ChartOmeros Corporation Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Omeros Corporation. The current mfi is 45.15.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Omeros Corporation Daily Money Flow Index (MFI) ChartOmeros Corporation Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Omeros Corporation.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-06BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-07RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-11SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-12-12STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-13CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-14SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2023-12-15RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-18STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-19CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-20STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-21STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-22BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-26STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-27RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-28STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-29RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-03MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-04CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-08ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-09MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-17STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-18MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-22MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-23SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-26DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-01-31DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-06DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-09DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-12MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-13STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-20RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-02-21ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-26STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-04SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-06CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-07STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-11STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-12CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-14DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-22CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-27STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-28STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-01CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-03MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-04-04SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-04-05ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-09MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-04-10CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-11DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-15DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-18SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-04-19MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-22WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-25STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Omeros Corporation Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Omeros Corporation based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5042.275
Ma 20Greater thanMa 503.298
Ma 50Greater thanMa 1003.781
Ma 100Greater thanMa 2003.540
OpenGreater thanClose3.070
Total2/5 (40.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Omeros with someone you think should read this too:
  • Are you bullish or bearish on Omeros? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Omeros? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Omeros Corporation

I send you an email if I find something interesting about Omeros Corporation.


Comments

How you think about this?

Leave a comment

Stay informed about Omeros Corporation.

Receive notifications about Omeros Corporation in your mailbox!